Analyst Ratings For bluebird bio Inc (NASDAQ:BLUE)
Today, bluebird bio Inc (NASDAQ:BLUE) stock was downgraded by Leerink Swann from Outperform to Market Perform.
There are 13 Buy Ratings, 7 Hold Ratings, 1 Strong Buy Ratings, 1 Sell Ratings on the stock.
The current consensus rating on bluebird bio Inc (NASDAQ:BLUE) is Buy with a consensus target price of $178.8771 per share, a potential 17.04% upside.
Some recent analyst ratings include
- 3/5/2019-bluebird bio Inc (NASDAQ:BLUE) gets downgraded to Market Perform by Leerink Swann
- 2/26/2019-bluebird bio Inc (NASDAQ:BLUE) has coverage initiated with a Outperform rating and $149.91 price target
- 2/22/2019-bluebird bio Inc (NASDAQ:BLUE) had its Neutral ➝ Neutral rating reiterated by Cantor Fitzgerald with a $122.00 price target
- 1/23/2019-bluebird bio Inc (NASDAQ:BLUE) had its Buy ➝ Buy rating reiterated by Canaccord Genuity with a $161.00 price target
- 1/11/2019-bluebird bio Inc (NASDAQ:BLUE) had its Hold rating reiterated by Oppenheimer
- On 2/28/2019 Kory James Wentworth, Insider, sold 51 with an average share price of $151.71 per share and the total transaction amounting to $7,737.21.
- On 2/25/2019 Jason Cole, Insider, sold 6,248 with an average share price of $150.24 per share and the total transaction amounting to $938,699.52.
- On 2/8/2019 Jeffrey T Walsh, Insider, sold 1,500 with an average share price of $131.29 per share and the total transaction amounting to $196,935.00.
- On 2/4/2019 David Davidson, Insider, sold 4,910 with an average share price of $134.30 per share and the total transaction amounting to $659,413.00.
- On 1/28/2019 Kory James Wentworth, Insider, sold 209 with an average share price of $125.96 per share and the total transaction amounting to $26,325.64.
- On 1/18/2019 David Davidson, Insider, sold 2,035 with an average share price of $130.05 per share and the total transaction amounting to $264,651.75.
- On 1/16/2019 Jeffrey T Walsh, Insider, sold 3,000 with an average share price of $125.14 per share and the total transaction amounting to $375,420.00.
About bluebird bio Inc (NASDAQ:BLUE)
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease. The company's lead product candidates in oncology include bb2121 and bb21217, which are anti- B-cell maturation antigens in Phase I clinical trials for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. It also has collaborations with Medigene AG for the research and development of T cell receptor product candidates directed against antigens for the treatment of cancer indications; TC BioPharm Limited to research and develop gamma delta chimeric antigen receptor modified T cell product candidates for cancer immunotherapy; Inhibrx, Inc. to research, develop, and commercialize CAR T Cell immunotherapies; and Gritstone Oncology, Inc. to research, develop, and commercialize products for the treatment of cancer using cell therapy, as well as a partnership agreement with Celgene European Investment Company LLC. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Recent Trading Activity for bluebird bio Inc (NASDAQ:BLUE)
Shares of bluebird bio Inc closed the previous trading session at 152,83 −3,83 2,44 % with shares trading hands.
